Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF Eye Drops in Dry Eye Disease
2023-507357-15-00Phase 4Withdrawn
- Sponsor
- BTI Biotechnology Institute
- Start
- Aug 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of PRGF-Endoret in dry eye syndrome (DED) (3 arms), sponsored by BTI Biotechnology Institute. Primary endpoints: Change in Ocular Surface Disease Index (OSDI) score at 12 weeks, Change in ocular surface staining (Oxford scale) at 12 weeks and 3 more. Planned start Aug 2024; status: withdrawn.
02
Drugs
PRGF-Endoret
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2023-507357-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507357-15-00.